Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 30 2025
0mins
Source: Globenewswire
Cognition Therapeutics' START Study Progress: Cognition Therapeutics has announced that its Phase 2 'START' Study for the treatment of early Alzheimer's disease has surpassed 50% enrollment, supported by a grant from the National Institute of Aging. The study aims to evaluate the efficacy of zervimesine (CT1812) in individuals with mild cognitive impairment.
Potential Benefits of Zervimesine: Preliminary results from previous studies suggest that zervimesine may significantly slow cognitive decline in patients with lower levels of the protein p-tau217, indicating a promising treatment response for those in the early stages of Alzheimer's disease.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
